Stockscreener 앱 받기
0.9222
8.69%
-0.0878
시간 외 거래:
.93
0.0078
+0.85%
전일 마감가:
$1.01
열려 있는:
$0.99
하루 거래량:
195.56K
Relative Volume:
3.01
시가총액:
$25.77M
수익:
$9.19M
순이익/손실:
$-36.65M
주가수익비율:
-0.5988
EPS:
-1.54
순현금흐름:
$-34.57M
1주 성능:
-28.51%
1개월 성능:
-30.14%
6개월 성능:
-0.84%
1년 성능:
+50.51%
1일 변동 폭
$0.8164
$1.1227
1주일 범위
$0.8164
$1.33
52주 변동 폭
$0.481
$1.88
Durect Corp Stock (DRRX) Company Profile
명칭
Durect Corp
전화
(408) 777-1417
주소
10240 BUBB ROAD, CUPERTINO, CA
DRRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| DRRX | 0.9222 | 25.77M | 9.19M | -36.65M | -34.57M | -1.54 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Durect Corp Stock (DRRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-10-30 | 개시 | Chardan Capital Markets | Buy |
| 2020-10-12 | 개시 | ROTH Capital | Buy |
| 2020-07-31 | 개시 | Oppenheimer | Outperform |
| 2020-01-31 | 개시 | B. Riley FBR | Buy |
| 2019-11-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-09-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-06 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2017-10-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2017-10-20 | 재확인 | Laidlaw | Buy |
| 2017-10-20 | 다운그레이드 | Stifel | Buy → Hold |
| 2017-07-12 | 업그레이드 | Stifel | Hold → Buy |
| 2017-02-28 | 재개 | H.C. Wainwright | Buy |
| 2016-04-25 | 개시 | Rodman & Renshaw | Buy |
| 2015-05-01 | 재확인 | Cantor Fitzgerald | Buy |
| 2015-05-01 | 재확인 | Stifel | Buy |
| 2013-03-25 | 개시 | Stifel | Buy |
| 2012-11-01 | 다운그레이드 | C.K. Cooper | Buy → Hold |
| 2012-08-17 | 개시 | C.K. Cooper | Buy |
| 2009-06-23 | 개시 | Caris & Company | Buy |
| 2009-03-26 | 개시 | Wedbush Morgan | Hold |
모두보기
Durect Corp 주식(DRRX)의 최신 뉴스
DURECT Corporation (NASDAQ:DRRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corporation reports Q3 2024 financials - Investing.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Cost Reductions and ... - Yahoo Finance
Durect: Q3 Earnings Snapshot - Houston Chronicle
Durect Corp Q3 2024 Earnings: GAAP EPS of -$0.14 Misses Estimates, Revenue at $1.9 Million Below Expectations - GuruFocus.com
Durect (DRRX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Durect reports Q3 EPS (14c), consensus (17c) - TipRanks
DURECT Q3: $4.3M Loss, Plans Phase 3 Trial Amid Funding Needs & License Agreement End | DRRX Stock News - StockTitan
DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update - StockTitan
DRRXDurect Corp Latest Stock News & Market Updates - StockTitan
DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024 - StockTitan
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Gro - GuruFocus.com
Durect Corp (DRRX) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Advances Amid ... - Yahoo Finance
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - PR Newswire
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PR Newswire
Durect Corp (NQ: DRRX - Financial Content
Durect (FRA:DC8A) Total Inventories : €2.30 Mil (As of Jun. 2024) - GuruFocus.com
DURECT Co. (NASDAQ:DRRX) Expected to Post Q3 2024 Earnings of ($0.14) Per Share - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corp reports steady Q2 financials, plans Phase III trial - Investing.com India
Durect: Q2 Earnings Snapshot - Houston Chronicle
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT (DRRX) Set to Announce Quarterly Earnings on Tuesday - Defense World
DURECT Co. (NASDAQ:DRRX) Receives $27.50 Average Target Price from Brokerages - American Banking and Market News
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - StockTitan
ProAssurance Co. (NYSE:PRA) Shares Bought by CANADA LIFE ASSURANCE Co - Defense World
DURECT (DRRX) Stock Price, News & Analysis - MarketBeat
Altair Engineering (NASDAQ:ALTR) Stock Rating Lowered by The Goldman Sachs Group - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above Two Hundred Day Moving Average of $1.13 - MarketBeat
DURECT Co. (NASDAQ:DRRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above 200-Day Moving Average of $1.01 - Defense World
Durect - The Pharma Letter
DURECT Corporation Announces Presentations in Upcoming Investor Conferences - Quantisnow
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol ... - Quantisnow
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update - Quantisnow
Are Medical Stocks Lagging DURECT (DRRX) This Year? - Yahoo Canada Finance
Short Interest in DURECT Co. (NASDAQ:DRRX) Increases By 15.1% - MarketBeat
DURECT Co. (NASDAQ:DRRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
DURECT Co. (NASDAQ:DRRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Drug ManufacturersOther Equities Technical Momentum -- DepoMed, Pernix Therapeutics Holdings, Novo Nordisk ... - br.ADVFN.com
DURECT Corporation Announces Update on DUR-928 Development Program - br.ADVFN.com
Financial Metrics Exploration: Understanding Durect Corp (DRRX) Through Ratios – DWinneX - The Dwinnex
DURECT (NASDAQ:DRRX) Stock Crosses Above Two Hundred Day Moving Average of $0.86 - Defense World
Durect Corp (DRRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
0.15%
자본화:
|
볼륨(24시간):